Streptomycin stands as a landmark achievement in medical history, recognized as the first antibiotic capable of effectively treating tuberculosis (TB). Its isolation in 1943 marked a pivotal moment, offering hope against a disease that had long plagued humanity. This discovery not only provided a cure for TB but also paved the way for further antibiotic research, fundamentally changing the landscape of infectious disease treatment. The journey from
its initial isolation to its widespread application involved dedicated scientific effort, early clinical trials, and the eventual recognition of its profound impact on global health.
The Genesis of a Lifesaving Drug
The story of streptomycin begins on October 19, 1943, when Albert Schatz, a PhD student working in the laboratory of Selman Abraham Waksman at Rutgers University, successfully isolated the compound. This research project was supported by Merck and Co. Waksman and his team were prolific in their discovery of antibiotics, identifying several, including actinomycin, clavacin, streptothricin, grisein, neomycin, fradicin, candicidin, and candidin. Among these, streptomycin and neomycin proved to have extensive applications in treating numerous infectious diseases. Streptomycin earned its name from its source, *Streptomyces griseus*, and an earlier antibiotic discovered by Waksman, streptothricin. The scientific community was formally introduced to this new antibiotic on January 1, 1944, when its discovery was reported in the journal *Experimental Biology and Medicine*.
Streptomycin's significance was immediately apparent due to its broad-spectrum activity. It demonstrated the ability to inhibit both Gram-positive and Gram-negative bacteria, making it a versatile tool against a range of infections. However, its most celebrated attribute was its efficacy against *Mycobacterium tuberculosis*, the bacterium responsible for tuberculosis. This made streptomycin the first antibiotic cure for TB, a disease that had previously been notoriously difficult to treat. The profound impact of this discovery was recognized when Selman Waksman was awarded the Nobel Prize in Physiology or Medicine in 1952, specifically for his discovery of streptomycin and its activity against tuberculosis.
From Laboratory to Clinic: Early Trials and Production Challenges
Following its isolation, the Rutgers team quickly moved to report streptomycin in medical literature in January 1944. Within months, they began collaborating with William Feldman and H. Corwin Hinshaw of the Mayo Clinic, aiming to initiate human clinical trials for tuberculosis. A significant hurdle at this stage was the limited availability of the drug. The methods used in research laboratories to produce small batches were not yet scaled for commercial, large-batch production. Despite these challenges, they managed to conduct an animal study using just 10 grams of the scarce drug, demonstrating survival in a few guinea pigs. This crucial evidence was sufficient to persuade Merck & Co. to reallocate some resources from their burgeoning penicillin production program to begin efforts toward streptomycin production.
As World War II concluded, the United States Army began experimenting with streptomycin to treat life-threatening infections. One notable early application occurred at a military hospital in Battle Creek, Michigan. The initial patient treated with streptomycin did not survive, and the second patient, while surviving, experienced blindness as a side effect. However, in March 1946, the third patient, Robert J. Dole, who would later become a prominent U.S. Senator and presidential nominee, showed a rapid and robust recovery, highlighting the drug's potential. The first randomized trial of streptomycin against pulmonary tuberculosis was conducted between 1946 and 1948 by the MRC Tuberculosis Research Unit. Although this trial was not double-blind or placebo-controlled, it is widely acknowledged as the first randomized curative trial. The results confirmed streptomycin's efficacy against TB, though minor toxicity and the development of bacterial resistance to the drug were also noted.
The Mechanism of Action and Broader Applications
Streptomycin functions as a protein synthesis inhibitor. It irreversibly binds to the small 16S rRNA of the 30S ribosomal subunit, which interferes with the binding of formyl-methionyl-tRNA to this subunit. This disruption leads to codon misreading, halting protein synthesis, and ultimately causing cell death through mechanisms that are not fully understood. It is speculated that the binding of streptomycin to the 30S subunit destabilizes the ribosomal-mRNA complex, leading to premature termination of protein synthesis. While both human and bacterial cells possess ribosomes, streptomycin primarily inhibits bacterial growth at low concentrations, though it can have significant side effects in humans at higher doses.
Beyond its primary role in treating tuberculosis, streptomycin has found other applications. It is used as a pesticide to control bacterial diseases in certain fruits, vegetables, seeds, and ornamental crops, with a major use being the control of fireblight on apple and pear trees. In laboratory settings, streptomycin sulfate is sometimes added to biological extracts to remove nucleic acids and ribonuclear proteins, as it binds to ribosomes and precipitates out of solution. This allows for the removal of rRNA, mRNA, and even DNA from prokaryotic extracts. However, extensive use in any application can lead to the development of resistant strains, a challenge that continues to be addressed in antibiotic stewardship.
